bluebird bio Appoints William R. Sellers, M.D. to Board of Directors
September 27 2019 - 7:00AM
Business Wire
bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has
appointed William R. Sellers, M.D. to its Board of Directors.
“I’m excited to welcome Bill to the Board to help navigate an
important stage in bluebird’s evolution,” said Nick Leschly, chief
bluebird. “Bill is a pioneer in cancer genomics and translational
medicine, as well as an experienced industry research and
development leader, and we look forward to his contributions in
supporting all of us at bluebird to achieve our goals for
patients.”
“I have been impressed with bluebird’s passion for translating
innovative science into improved treatments for patients through
the company’s gene editing, gene addition and cellular
immunotherapy platforms,” said Dr. Sellers. “I look forward to
working with such a talented team to progress the company’s early
research pipeline and robust BCMA clinical development program, and
to discover the next generation of gene and cell therapies.”
Dr. Sellers leads a research group focused on translating
genomic discoveries into new therapeutics as a Core Institute
Member at the Broad Institute of MIT and Harvard, and as a
Professor of Medicine at the Dana-Farber Cancer Institute and
Harvard Medical School. Previously, Dr. Sellers directed cancer
drug discovery and early cancer clinical development at the
Novartis Institutes for Biomedical Research overseeing scientists,
clinicians and clinical staff on sites in Cambridge, East Hanover,
Basel and Shanghai from 2005-2016. During his tenure he
conceptualized and directed a collaboration with the Broad
Institute on the Cancer Cell Line Encyclopedia, the development of
the Novartis Primary Derived Xenograft Encyclopedia and large-scale
efforts to functionally characterize the cancer genome. Along with
Dr. Carl June, he co-chaired the CART research collaboration with
the University of Pennsylvania that brought CTL019 to a recent FDA
approval.
Dr. Sellers was previously an Associate Professor of Medicine at
the Dana-Farber Cancer Institute and Harvard Medical School and an
Associate Member of the Broad Institute. Together with Matthew
Meyerson, he initiated and developed large-scale efforts to
re-sequence genes in diverse cancer types, which led to the
development of the widely used GISTIC algorithm, the discovery of
EGFR mutations in lung adenocarcinoma and the discovery of the
oncogenic role of the MITF gene in melanoma. In addition, his work
advanced the understanding of the molecular mechanisms of growth
regulation of the PTEN tumor suppressor gene.
Dr. Sellers received his B.S. from Georgetown University in 1982
and M.D. from the University of Massachusetts Medical School in
1986. He completed residency training in Internal Medicine at the
University of California San Francisco in 1989 and trained in
Medical Oncology at the Dana-Farber Cancer Institute. Dr. Sellers
is a former member of the National Cancer Advisory Board.
About bluebird bio, Inc. bluebird bio is pioneering gene
therapy with purpose. From our Cambridge, Mass., headquarters,
we’re developing gene therapies for severe genetic diseases and
cancer, with the goal that people facing potentially fatal
conditions with limited treatment options can live their lives
fully. Beyond our labs, we’re working to positively disrupt the
healthcare system to create access, transparency and education so
that gene therapy can become available to all those who can
benefit.
bluebird bio is a human company powered by human stories. We’re
putting our care and expertise to work across a spectrum of
disorders by researching cerebral adrenoleukodystrophy, sickle cell
disease, transfusion-dependent β-thalassemia and multiple myeloma
using three gene therapy technologies: gene addition, cell therapy
and (megaTAL-enabled) gene editing.
bluebird bio has additional nests in Seattle, Wash.; Durham,
N.C.; and Zug, Switzerland. For more information, visit
bluebirdbio.com.
Follow bluebird bio on social media: @bluebirdbio,
LinkedIn, Instagram and YouTube.
bluebird bio is a trademark of bluebird bio, Inc.
Forward-Looking Statements This release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
regarding the advancement of, and anticipated development and
commercialization plans for, the Company’s product candidates. Any
forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include,
but are not limited to, the risks that results from our prior and
ongoing clinical trials of our product candidates will not continue
or be repeated in our ongoing or planned clinical trials; risks
that the current or planned clinical trials of our product
candidates will be insufficient to support future regulatory
submissions or to support marketing approval in the U.S. and EU and
the risk that our product candidates will not be successfully
developed, approved or commercialized. For a discussion of other
risks and uncertainties, and other important factors, any of which
could cause our actual results to differ from those contained in
the forward-looking statements, see the section entitled “Risk
Factors” in our most recent Form 10-K as well as discussions of
potential risks, uncertainties and other important factors in our
subsequent filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release,
and bluebird bio undertakes no duty to update this information
unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190927005033/en/
bluebird bio Investors: Elizabeth Pingpank, 617-914-8736
epingpank@bluebirdbio.com or Media: Jennifer Snyder,
617-448-0281 jsnyder@bluebirdbio.com
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Mar 2024 to Apr 2024
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Apr 2023 to Apr 2024